Abstract
Three-dimensional protein structural data at the molecular level are pivotal for successful precision medicine. Such data are crucial not only for discovering drugs that act to block the active site of the target mutant protein but also for clarifying to the patient and the clinician how the mutations harbored by the patient work. The relative paucity of structural data reflects their cost, challenges in their interpretation, and lack of clinical guidelines for their utilization. Rapid technological advancements in experimental high-resolution structural determination increasingly generate structures. Computationally, modeling algorithms, including molecular dynamics simulations, are becoming more powerful, as are compute-intensive hardware, particularly graphics processing units, overlapping with the inception of the exascale era. Accessible, freely available, and detailed structural and dynamical data can be merged with big data to powerfully transform personalizedpharmacology. Here we review protein and emerging genome high-resolution data, along with means, applications, and examples underscoring their usefulness in precision medicine.
Original language | English |
---|---|
Pages (from-to) | 95-117 |
Number of pages | 23 |
Journal | Annual review of biomedical data science |
Volume | 5 |
DOIs | |
State | Published - 10 Aug 2022 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2022 by Annual Reviews. All rights reserved.
Funding
This project has been funded in whole or in part with federal funds from the National Cancer Institute (NCI) of the National Institutes of Health (NIH), under contract HHSN261201500003I. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported (in part) by the Intramural Research Program of the NCI's Center for Cancer Research. This project has been supported in part by the National Institute of Aging (NIA) of the NIH under award numbers U01AG073323, R01AG066707, 3R01AG066707-01S1, 3R01AG066707-02S1, and 1R56AG074001-01 to F.C.
Funders | Funder number |
---|---|
National Institutes of Health | HHSN261201500003I |
U.S. Department of Health and Human Services | |
National Institute on Aging | 1R56AG074001-01, R01AG066707, U01AG073323 |
National Cancer Institute | |
Government of South Australia |
Keywords
- AI
- KRas
- cancer
- chromatin accessibility
- drug resistance
- free-energy landscape
- machine learning
- network medicine
- signaling
- targeted therapy